• Ingredion Incorporated has appointed Diego Reynoso, a veteran finance leader from The Boston Beer Company, Tyson Foods and Constellation Brands, as chief financial officer and executive vice president effective October 1, 2026, replacing interim CFO Jason Payant who will return to a divisional finance leadership role.
• This hire brings deep food and beverage finance and operations expertise into Ingredion’s C‑suite, reinforcing management’s focus on growth, productivity and disciplined capital allocation during its ongoing shift toward higher-value ingredient solutions.
• We’ll now examine how Reynoso’s appointment as CFO and executive vice president could influence Ingredion’s existing investment narrative and future priorities.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Ingredion Investment Narrative Recap

To own Ingredion, you need to believe its shift toward higher value, health focused ingredient solutions can offset pressure in legacy starches and sweeteners. Reynoso’s appointment adds seasoned food and beverage finance leadership but does not materially change the near term earnings risk from weaker volumes, FX headwinds and softer net margins flagged in recent results.

The most relevant recent announcement alongside Reynoso’s hire is Q2 2026 earnings, where sales were roughly flat but net income fell from US$196 million to US$114 million. That backdrop makes his role in capital allocation, productivity and integration especially important as Ingredion invests in Texture & Healthful Solutions and manages debt tied to the Tate & Lyle financing package.

Yet behind the appealing specialty ingredients story, investors still need to be aware of the risk that prolonged FX and pricing pressure could...

Ingredion's narrative projects $7.8 billion revenue and $789.5 million earnings by 2029. This requires 2.5% yearly revenue growth and a roughly $115 million earnings increase from $674.0 million today.

Uncover how Ingredion's forecasts yield a $122.83 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$7.4 billion and earnings near US$774 million by 2029, and they saw execution and margin risks as more limiting than the consensus view, particularly if cost inflation and operational issues linger even as Ingredion pursues higher value solutions and brings in a new CFO.

Explore 5 other fair value estimates on Ingredion - why the stock might be worth 17% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ingredion research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Ingredion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ingredion's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.